Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: OmertaSoldier who wrote (19048)	2/24/1999 12:52:00 AM
From: AlienTech	Respond to of 23519

>>The active ingredient of the product, phentolamine, has previously been marketed by other drug makers as a treatment for hypertension.<< Guess from now on you can buy the same pill for all your ails.

To: OmertaSoldier who wrote (19048)	2/24/1999 1:28:00 AM
From: VLAD	Respond to of 23519

OS, Those who have been following Zonagen and Vasoscam over the past year know that this one isn't going to get away with the hype considering: 1)Vasomax only showed a 13% improvement over placebo in Zonagen's P3 studies. 2)Vasomax just as Viagra can create hypotension which can prove fatal in the CAD patient. 3)So far in the only market that the product has been marketed in (Mexico), sales are miniscule. I feel that as more oral drugs receive approval it will shed more and more light on the importance of a good safety profile--this is where with good domestic marketing partner, Vivus will be able to regain a lot of the market share lost to Viagra.